Linkedin
RLS logo_header
Linkedin

Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

“We are proud to partner with Roche, a global leader in oncology, to accelerate the application of novel cancer targets identified through our proprietary discovery platform, OGAP-Verify,” said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics. “This collaboration builds on our efforts to enhance, validate and advance the discovery of oncology targets, and we look forward to leveraging Roche’s deep expertise to translate these insights into potential new treatments for patients. Our discovery philosophy is very patient centric and Roche’s strength to integrate pharma and diagnostics is unique in the industry.”

Read the full story on "Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer"

Share:

More News

FDA Accepts NDA for Giredestrant in ER-Positive Early-Stage Breast Cancer

“Giredestrant represents the first major endocrine therapy advance in early-stage ER-positive breast cancer in decades, where the chance for cure is highest,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “The FDA’s filing acceptance brings us closer to delivering a new standard-of-care with the

SOTIO Receives U.S. FDA Orphan Drug Designation for SOT106 for Sarcoma

“Orphan Drug Designation for SOT106 underscores both the urgent need for new treatment options in osteosarcoma and the strength of our ADC platform,” said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. “Osteosarcoma is a devastating disease that has seen little therapeutic innovation over the past four decades. Treatment

FDA Granted Fast Track Designation for TER-2013 for HR+ve/HER2neg Breast Cancer

“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”

FDA Clears amendment to Open U.S. Enrollment in Ongoing Ph 2 THIO-101 Trial Expansion

“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two